共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 高密度脂蛋白胆固醇和甘油三酯与心血管病剩余风险的关系显示文摘目的分析高密度脂蛋白胆固醇(HDL-C)和甘油三酯(TG)与心血管病剩余风险的关系,探讨HDL-C、TG对心血管病剩余风险的预测价值。方法选择60例低密度脂蛋白胆固醇(LDL-C)<2.60 mmol/L的冠状动脉粥样硬化性心脏病(CHD)患者,分为急性心肌梗死组(n=22)、稳定性心绞痛组(n=38),测定血脂和血糖指标,详细记录临床特征并进行分析。结果急性心肌梗死组HDL-C水平低于稳定性心绞痛组(P<0.05),急性心肌梗死组TG/HDL-C的比值显著高于稳定性心绞痛组(P<0.01)。急性心肌梗死的危险性与TG/HDL-C的比值呈正相关(回归系数β值=0.033 2,P<0.001),与HDL-C呈负相关(回归系数β值=-0.095 5,P=0.022),而与总胆固醇(TC)、TG和LDL-C无显著相关。结论 HDLC水平低和TG/HDL-C的比值高是CHD患者发生心血管事件的危险因素,TG/HDL-C的比值能更强地预测CHD患者的心血管病剩余风险。 | 容春莉 | 2015 | 中国老年学杂志2015，35，2： | 10 |
| 2 | Use of fibrates in the metabolic syndrome:A review显示文摘The use of fibrates in the treatment of dyslipidaemia has changed significantly over recent years.Their role appeared clear at the start of this century.The Helsinki Heart Study and Veterans Affairs High-Density Cholesterol Intervention Trial suggested significant benefit,especially in patients with atherogenic dyslipidaemia.However,this clarity disintegrated following the negative outcomes reported by the Bezafibrate Infarction Prevention,Fenofibrate Intervention and Event Lowering in Diabetes and Action to Control Cardiovascular Risk in Diabetes randomised controlled trials.In this review we discuss these and other relevant trials and consider patient subgroups such as those with the metabolic syndrome and those needing treatment to prevent the microvascular complications associated with diabetes in whom fibrates may be useful.We also discuss observations from our group that may provide some explanation for the varying outcomes reported in large trials.The actions of fibrates in patients who are also on statins are interesting and appear to differ from those in patients not on statins.Understanding this is key as statins are the primary lipid lowering agents and likely to occupy that position for the foreseeable future.We also present other features of fibrate treatment we have observed in our clinical practice;changes in creatinine,liver function tests and the paradoxical high density lipoprotein reduction.Our purpose is to provide enough data for the reader to make objective decisions in their own clinical practice regarding fibrate use. | Kate E Shipman Richard C Strange Sudarshan Ramachandran | 2016 | World Journal of Diabetes2016，7，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员